RADIATION & RISK
Bulletin of the National Radiation and Epidemiological Registry
since 1992
About the Journal : 2011 : vol. 20, No. 1 : Analysis of TCR-mutant lymphocyte frequency in cancer patients before and after chemoradiotherapy

Analysis of TCR-mutant lymphocyte frequency in cancer patients before and after chemoradiotherapy

«Radiation and Risk», 2011, vol. 20, no. 1, pp.8-18

Authors

Zamulaeva I.A. – Head of Lab., D. Sc., Biol., Prof. Medical Radiological Research Center of the Russian Ministry of Health and Social Development, Obninsk, Russia.
Smirnova S.G. – Senior Res., C. Sc., Biol. Contacts: 4 Korolyov str., Obninsk, Kaluga region, Russia, 249036. Tel.: (48439) 9-77-81, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. . Medical Radiological Research Center of the Russian Ministry of Health and Social Development, Obninsk, Russia.
Orlova N.V. – Senior Res., C. Sc., Biol. Medical Radiological Research Center of the Russian Ministry of Health and Social Development, Obninsk, Russia.
Bogatyreva T.I. – Lead. Res., MD. Medical Radiological Research Center of the Russian Ministry of Health and Social Development, Obninsk, Russia.
Pavlov V.V. – Head of Dep., C. Sc., Med. Medical Radiological Research Center of the Russian Ministry of Health and Social Development, Obninsk, Russia.
Terekhova A.Y. – Senior Res., C. Sc., Med. Medical Radiological Research Center of the Russian Ministry of Health and Social Development, Obninsk, Russia.
Makarenko S.A. – Res. Ass. Medical Radiological Research Center of the Russian Ministry of Health and Social Development, Obninsk, Russia.
Saenko A.S. – Deputy Director, D. Sc., Biol., Prof. Medical Radiological Research Center of the Russian Ministry of Health and Social Development, Obninsk, Russia.

Abstract

Comparative analysis of frequency of lymphocytes, bearing mutations at T-cell receptor locus (TCR), in patients with Hodgkin’s lymphoma was conducted before treatment and after chemoradiotherapy. It was shown that 20 % of patients before the treatment had increased frequencies of mutant cells, which are comparable with the results obtained for patients with malignant tumors of other localizations. Significant genotoxic effect of anticancer therapy was found after the treatment. A tendency to increase of the mutant cell frequency was observed in patients receiving more extensive-field radiotherapy. It was shown high individual variability (more than 7-fold differences) of this parameter of somatic mutagenesis at the same time after the treatment. These data suggest the possibility of using TCR-mutant cell frequency for individual assessment of risk for secondary malignancies.

Key words
Hodgkin’s lymphoma, chemoradiotherapy, secondary malignancies, somatic mutation, T-cell receptor.

References

1. Bogatyreva T.I. Combined and radiotherapy of primary and recurrent lymphoma of Chodzhkin on the basis of intensive dose fractionation regimes: author's abstract. dis. ... Doct. med. sciences. Obninsk, 2006. 40 p.

2. Vereshchagina A.O., Zamulaeva I.A., Orlova N.V. The frequency of lymphocytes mutated in genes T-cell receptor as a possible criterion for the formation of a group of increased risk of developing thyroid tumors in irradiated and non-irradiated individuals. Radiation Biology. Radioecology. 2005. Vol. 45, no. 5. PP. 581-586.

3. Demina E.A. Hodgkin's lymphoma: from Thomas Hodgkin to the present day. Clinical oncohematology. 2008. Vol. 1, no. 2. PP. 114-118.

4. Zamulaeva I.A., Smirnova S.G., Orlova N.V. An increased frequency of mutant loci T-cell receptor and glycophorin A cells as a possible criterion for the formation of a risk group of oncological diseases. Journal of Russian Oncology. 2001. No. 1. PP. 23-25.

5. Kovryzhkina T.A., Ilyin N.V., Verbovetskaya V.I. and others. Second tumors in patients with lymphogranuloma-matos. Questions of oncology. 2001. No. 5. PP. 626-630.

6. Pavlov V.V., Bogatyreva T.I., Shakhtarina S.V., Danilenko A.A. Optimization of the radial component in programs of combined chemoradiation treatment of patients with Hodgkin's lymphoma. Therapeutic Radiology. Manual for doctors. Ed. A.F. Tsyb, Y.S. Mardynsky. Moscow, MK Publ., 2010. PP. 461-505.

7. Sayenko A.S., Zamulaeva I.A., Smirnova S.G. et al. Determination of the frequency of mutations in the glycosorin A and T-cell receptor loci: informativity for biological dosimetry of acute and prolonged irradiation.Radiation Biology. Radioecology. 1998. Vol. 38. PP. 171-180.

8. Shakhtarina S.V., Danilenko A.A., Pavlov V.V. Malignant neoplasms in patients with Hodgkin's lymphoma after radiotherapy with a radical program and combined chemoradiotherapy. Clinical oncohematology. 2008. Vol. 1, no. 3. PP. 246-251.

9. Akiyama M., Umeki S., Kusunoki Y. et al. Somatic-cell mutations as a possible predictor of cancer risk.Health Physics. 1995. Vol. 68, no. 5. PP. 643-649.

10. Albertini R.J. HPRT mutations in humans: biomarkers for mechanistic studies. Mutat. Res. 2001. Vol. 489, no. 1. PP. 1-16.

11. Caggana M., Liber H.L., Mauch P.M., Coleman C.N., Kelsey K.T. In vivo somatic mutation in the lymphocytes of Hodgkin's disease patients. Environ. Mol. Mutagen. 1991. Vol. 18, No. 1. PP. 6-13.

12. Dietrich P.Y., Henry-Amar M., Cosset J.M. et al. Second primary cancers in patients continuously disease-free from Hodgkin's disease: a protective role for the spleen? Blood. 1994. Vol. 84, no. 4. PP. 1209-1215.

13. Engert A., Diehl V., Franklin J. et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J. Clin. Oncol. 2009. Vol. 27, no. 27. PP. 4548-4554.

14. Franklin J., Pluetschow A., Paus M. et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann. Oncol. 2006. Vol. 17, no. 12. PP. 1749-1760.

15. Iwamoto K.S., Hirai Y. Umeki S. et al. A positive correlation between T-cell receptor mutant frequencies and dicentric chromosome frequencies in lymphocytes from radiotherapy patients. J. Radiat. Res. 1994. Vol. 35. PP. 92-103.

16. Kyoizumi S., Akiyama M., Hirai Y. et al. Spontaneous loss and alteration of antigen receptor expression in mature CD4+ T-cells. J. Exp. Med. 1990. Vol. 171. PP. 1981-1999.

17. Mott M.G., Boyse J., Hewitt M., Radford M. Do mutations at the glycophorin A locus in patients treated for childhood Hodgkin's disease predict secondary leukaemia? Lancet. 1994. V. 343. P. 828-829.

18. Ng A.K., Mauch P.M. The impact of treatment on the risk of second malignancy after Hodgkin's disease. Ann. Oncol. 2006. Vol. 17, No. 12. PP. 1727-1729.

19. Sawada M., Kubota M., Lin Y.W. et al. Prospective study of mutant frequencies at the HPRT and T-cell receptor gene loci in pediatric cancer patients during chemotherapy. Cancer Epidemiol. Biomarkers Prev. 1998. Vol. 7, no. 8. PP. 711-717.

Full-text article (in Russian)